cemiplimab,fianlimab
sanofi,regeneron
['fianlimab', 'melanoma', 'cemiplimab', 'imab ']
intriguing phase 1 data with fianlimab + cemiplimab (anti-lag3/pd-1) in met #melanoma presented at by et al. in pd-1 axis naive patients, orr 63%. in pd-1 treated, orr 13%. no new safety signals grade 3-5 ae 45%. #smr22
Medical Oncologist and Associate Professor @NorthwesternMed. Melanoma/Merkel. Immuno- and Targeted therapy. Clinical trials. HemeOnc Fellowship Program Director